Advertisement

New Daily Persistent Headache

  • Lauren R. Natbony
  • Huma U. Sheikh
  • Mark W. Green
Chapter

Abstract

New daily persistent headache (NDPH) is a unique form of chronic daily headache. The distinguishing feature of NDPH is a headache that starts abruptly, and patients can often recall the exact day of headache onset. Clinically, NPDH lacks characteristic features and may resemble migraine or tension-type headache. Diagnosis relies on first eliminating secondary mimics. Several different classes of medications have been used for treatment of NDPH with varying results. In clinical practice, treatment is often chosen based on the headache phenotype. However, most therapies are ineffective or minimally effective thereby making NDPH one of the most refractory types of headache to treat.

Keywords

New daily persistent headache Headache Chronic daily headache 

References

  1. 1.
    Vanast W. New daily-persistent headaches: definition of a benign syndrome. Headache. 1986;26:318.Google Scholar
  2. 2.
    Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.CrossRefGoogle Scholar
  3. 3.
    Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999;39(3):190–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Bigal ME, Sheftell FD, Rapoport AM, Lipton RB, Tepper SJ. Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache. Cephalalgia. 2002;22(6):432–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Grande RB, Aaseth K, Lundqvist C, Russell MB. Prevalence of new daily persistent headache in the general population. The Akershus study of chronic headache. Cephalalgia. 2009;29(11):1149–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Koenig MA, Gladstein J, McCarter RJ, Hershey AD, Wasiewski W. Pediatric Committee of the American Headache Society. Chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache. 2002;42(6):491–500.CrossRefPubMedGoogle Scholar
  7. 7.
    Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63(5):843–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Li D, Rozen TD. The clinical characteristics of new daily persistent headache. Cephalalgia. 2002;22(1):66–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Evans RW. New daily persistent headache. Headache. 2012;52(Suppl 1):40–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Robbins MS, Grosberg BM, Napchan U, Crystal SC, Lipton RB. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010;74(17):1358–64.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rozen TD. New daily persistent headache: a lack of an association with white matter abnormalities on neuroimaging. Cephalalgia. 2016;36(10):987–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Siberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache. 1994;34(1):1–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.Google Scholar
  14. 14.
    Kung E, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. New daily persistent headache in the paediatric population. Cephalalgia. 2009;29(1):17–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Robbins MS, Evans RW. The heterogeneity of new daily persistent headache. Headache. 2012;52(10):1579–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Young WB. New daily persistent headache: controversy in the diagnostic criteria. Curr Pain Headache Rep. 2011;15(1):47–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Grengs LR, Mack KJ. New daily persistent headache is most likely to begin at the start of school. J Child Neurol. 2016;31(7):864–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Uniyal R, Paliwal VK, Tripathi A. Psychiatric comorbidity in new daily persistent headache: a cross-sectional study. Eur J Pain. 2017;21:1031.CrossRefPubMedGoogle Scholar
  19. 19.
    Robbins MS. New daily-persistent headache and anxiety. Cephalalgia. 2011;31(7):875–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Goadsby PJ. New daily persistent headache: a syndrome, not a discrete disorder. Headache. 2011;51(4):650–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Rozen TD. Triggering events and new daily persistent headache: age and gender differences and insights on pathogenesis-a clinic-based study. Headache. 2016;56(1):164–73.CrossRefPubMedGoogle Scholar
  22. 22.
    Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007;47(7):1050–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Rozen TD. New daily persistent headache: an update. Curr Pain Headache Rep. 2014;18(7):431.CrossRefPubMedGoogle Scholar
  24. 24.
    Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Suppl 1):S3–8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rozen T, Roth J, Denenberg N. Joint hypermobility as a predisposing factor for the development of new daily persistent headache. Headache. 2005;45:828–9.Google Scholar
  26. 26.
    Piovesan EJ, Kowacs PA, Oshinsky ML. Convergence of cervical and trigeminal sensory afferents. Curr Pain Headache Rep. 2003;7(5):377–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Mack KJ. New daily persistent headache in children and adults. Curr Pain Headache Rep. 2009;13(1):47–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Southerland AM, Login IS. Rigorously defined hemicrania continua presenting bilaterally. Cephalalgia. 2011;31(14):1490–2.CrossRefPubMedGoogle Scholar
  30. 30.
    Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA. 2006;295(19):2286–96.CrossRefPubMedGoogle Scholar
  31. 31.
    Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser MG. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. J Neurol Neurosurg Psychiatry. 2005;76(8):1084–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Digre KB. Idiopathic intracranial hypertension headache. Curr Pain Headache Rep. 2002;6(3):217–25.CrossRefPubMedGoogle Scholar
  33. 33.
    Almazov I, Brand N. Meningismus is a commonly overlooked finding in tension-type headache in children and adolescents. J Child Neurol. 2006;21(5):423–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.CrossRefPubMedGoogle Scholar
  35. 35.
    Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2010;67(5):648–56.PubMedGoogle Scholar
  36. 36.
    Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101.CrossRefPubMedGoogle Scholar
  37. 37.
    Hastriter E, Halker R, Vargas B, Dodick D. Headache prognosis in reversible cerebral vasoconstriction syndrome (RCVS) (abstract). Headache. 2011;51:49.Google Scholar
  38. 38.
    Silberstein SD. Headaches due to nasal and paranasal sinus disease. Neurol Clin. 2004;22(1):1–19, v.CrossRefPubMedGoogle Scholar
  39. 39.
    Mokri B. Headaches in cervical artery dissections. Curr Pain Headache Rep. 2002;6(3):209–16.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol. 2008;35(1–2):88–95.CrossRefPubMedGoogle Scholar
  41. 41.
    Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2001;45(2):140–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Rozen TD. Intranasal contact point headache: missing the “point” on brain MRI. Neurology. 2009;72(12):1107.CrossRefPubMedGoogle Scholar
  43. 43.
    Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.CrossRefPubMedGoogle Scholar
  44. 44.
    Evans RW, Seifert TD. The challenge of new daily persistent headache. Headache. 2011;51(1):145–54.CrossRefPubMedGoogle Scholar
  45. 45.
    Nierenburg H, Newman LC. Update on new daily persistent headache. Curr Treat Options Neurol. 2016;18(6):25.CrossRefPubMedGoogle Scholar
  46. 46.
    Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus. Jpn J Med. 1991;30(2):161–3.CrossRefPubMedGoogle Scholar
  47. 47.
    Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24(11):955–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study. Neurol Sci. 2004;25(Suppl 3):S281–2.CrossRefPubMedGoogle Scholar
  49. 49.
    Baron EP, Rothner AD. New daily persistent headache in children and adolescents. Curr Neurol Neurosci Rep. 2010;10(2):127–32.CrossRefPubMedGoogle Scholar
  50. 50.
    Rozen T. Successful treatment of new daily persistent headache with gabapentin and topiramate. Headache. 2002;42(4):389.Google Scholar
  51. 51.
    Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache. 2001;41(8):830–2.CrossRefPubMedGoogle Scholar
  52. 52.
    Rozen T. Doxycycline for treatment resistant new daily persistent headache. Neurology. 2008;70(Suppl 1):A348.Google Scholar
  53. 53.
    Rozen TD. New daily persistent headache: clinical perspective. Headache. 2011;51(4):641–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Marmura MJ, Passero FC Jr, Young WB. Mexiletine for refractory chronic daily headache: a report of nine cases. Headache. 2008;48(10):1506–10.CrossRefPubMedGoogle Scholar
  55. 55.
    Prakash S, Shah ND. Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain. 2010;11(1):59–66.CrossRefPubMedGoogle Scholar
  56. 56.
    Prakash S, Saini S, Rana KR, Mahato P. Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. J Headache Pain. 2012;13(6):477–85.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Silberstein SD, Silberstein JR. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. Headache. 1992;32(9):439–45.CrossRefPubMedGoogle Scholar
  58. 58.
    Eller M, Gelfand A, Riggins N, Goadsby P. An inpatient course of intravenous dihydroergotamine use for new daily persistent headache. Neurology. 2014;82(10 Suppl):P7.180.Google Scholar
  59. 59.
    Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–32.CrossRefPubMedGoogle Scholar
  60. 60.
    Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes--prolonged effects from a single injection. Pain. 2006;122(1–2):126–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Spears RC. Efficacy of botulinum toxin type A in new daily persistent headache. J Headache Pain. 2008;9(6):405–6.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Joshi SG, Mathew PG, Markley HG. New daily persistent headache and potential new therapeutic agents. Curr Neurol Neurosci Rep. 2014;14(2):425.CrossRefPubMedGoogle Scholar
  63. 63.
    Trucco M, Ruiz L. P009. A case of new daily persistent headache treated with botulinum toxin type A. J Headache Pain. 2015;16(Suppl 1):A119.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Tarshish S, Robbins M, Napchan U, Buse D, Grosberg B. Prophylaxis of new daily persistent headache (NDPH): response to clonazepam in four patients [abstract]. Cephalalgia. 2009;29(Suppl. 1):49.Google Scholar
  65. 65.
    Rozen TD, Beams JL. New daily persistent headache with a thunderclap headache onset and complete response to nimodipine (a new distinct subtype of NDPH). J Headache Pain. 2013;14:100.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Rapoport AM, Bigal ME, Volcy M, Sheftell FD, Feleppa M, Tepper SJ. Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. Headache. 2003;43(5):482–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME. Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. Headache. 2005;45(10):1400–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Gallagher RM, Mueller L. Managing intractable migraine with naratriptan. Headache. 2003;43(9):991–3.CrossRefPubMedGoogle Scholar
  69. 69.
    Ruff RL, Ruff SS, Wang XF. Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury. J Rehabil Res Dev. 2009;46(9):1071–84.CrossRefPubMedGoogle Scholar
  70. 70.
    Wintrich S, Rothner D. New daily persistent headaches-follow up and outcome in children and adolescents. Headache. 2010;50(Suppl. 1):s23.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Lauren R. Natbony
    • 1
  • Huma U. Sheikh
    • 2
  • Mark W. Green
    • 3
    • 4
    • 5
  1. 1.Neurology, Center for Headache and Facial PainIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.NeurologyMount SinaiNew YorkUSA
  3. 3.NeurologyIcahn School of Medicine at Mt. SinaiNew YorkUSA
  4. 4.AnesthesiologyIcahn School of Medicine at Mt. SinaiNew YorkUSA
  5. 5.Rehabilitation MedicineIcahn School of Medicine at Mt. SinaiNew YorkUSA

Personalised recommendations